WO1998010781A1 - Means for treating prostate hypertrophy and prostate cancer - Google Patents
Means for treating prostate hypertrophy and prostate cancer Download PDFInfo
- Publication number
- WO1998010781A1 WO1998010781A1 PCT/EP1997/004740 EP9704740W WO9810781A1 WO 1998010781 A1 WO1998010781 A1 WO 1998010781A1 EP 9704740 W EP9704740 W EP 9704740W WO 9810781 A1 WO9810781 A1 WO 9810781A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cetrorelix
- treatment
- regime
- weeks
- receptor blocking
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
Definitions
- the invention is related to a method of treating benign prostate hypertrophy (BPH) and prostate cancer as well as to means of use therefor. DESCRIPTION OF RELATED ART
- BPH is a disease conditioned by age and affects approximately 60 % of all men older than 60.
- Pathogenetically an elevated accumulation of dihydrotestosterone in the prostate tissue is assumed to cause enlargement of the prostate.
- the accumulation of dihydrotestosterone is thought to be the result of elevated intracellular bonding based on receptor increase.
- the increase in receptors is stimulated by the elevation of the estrogen levels relative to androgen levels which decrease with age.
- the urological symptoms consist in an elevated frequency of miction due to elevated residual urine, which bothers the patients especially during the night hours. This is accompanied by a weak flow of urine, a time-delayed start of miction, and repeated infections of the bladder and kidneys.
- Surgical elimination of the obstruction due to prostate enlargement is still considered the "gold standard" within the various modalities of treatment.
- Surgery is not effective for all patients. Open operation or a transurethral resection results in no improvement in approximately 10 to 15 % of the patients due to the presence of other causes, e.g. neurogenic bladder, infections.
- these invasive methods entail additional risks such as the occurrence of a retrograde ejaculation, diminished libido and urine incontinence.
- Less invasive methods exist, e.g. balloon dilatation and treatment with hyperthermia or microwaves.
- Dyssynergia ⁇ -receptor blockers can be used in the case of a rigid sphincter or bladder sphincter.
- Alternative drug regimens involve the use of 5- ⁇ -reductase inhibitors such as Finasteride to inhibit the formation of dihydrotestosterone. This regimen has the additional advantage of not negatively influencing the libido or potency.
- EP 0.401,653 teaches the use of Naftopidil for therapy of dysuria in BPH (oral daily 10 - 100 mg) .
- Dysuria is discussed in the background section.
- WO publication 91/100731 describes a combination therapy for the prophylaxis or treatment of BPH by the combined administration of 2 or more therapeutic substances.
- the substances are selected from the group of 5- ⁇ -reductase inhibitors, anti-estrogens, aromatase inhibitors, inhibitors of 17.S-hydroxysteroid dehydrogenase activity and, in a few instances, of an i-androgens and/or LHRH agonists / antagonists.
- the anti-androgens were preferably given 2 to 4 hours before the administration of the LHRH agonist.
- WO publication 91/00733 teaches the treatment of androgen- dependent diseases with a new anti-androgen which can also be used in the context of a combination therapy.
- the treatment includes the steps of inhibiting the testicular hormonal secretion by administering an antagonist of LHRH or an agonist of LHRH along with a pharmaceutically effective amount of an anti-androgen.
- WO publication 92/16233 describes the combined use of an inhibitor of 5- ⁇ -reductase and an anti-androgen for the treatment of prostate cancer.
- the combination of Finasteride with an anti- androgen, e.g. Flutamide, is also taught.
- the use of a composition of various LHRH agonists and of an anti -androgen for treating BPH is also suggested by US 4,472,382.
- WO publication 92/16213 teaches a method of treating BPH by administering an inhibitor of 5- ⁇ -reductase select from 173- substituted 4 -azasteroid, 173-substituted non-azasteroid, 17/3- acetyl-3-carboxy-androst-3 , 6 -diene together with a 1 adrenergic receptor blocker selected from Terazosin, Doxazosin, Prazosin, Bunazosin, Indoramin, Alfuzosin.
- an inhibitor of 5- ⁇ -reductase select from 173- substituted 4 -azasteroid, 173-substituted non-azasteroid, 17/3- acetyl-3-carboxy-androst-3 , 6 -diene together with a 1 adrenergic receptor blocker selected from Terazosin, Doxazosin, Prazosin, Bunazosin, Indoramin, Alfuzosin.
- LHRH antagonists including Cetrorelix
- Cetrorelix The potential suitability of LHRH antagonists, including Cetrorelix, for treating BPH appears in a review article appearing in Arch. -Pharmakol . 350, Suppl . , R16, 1994 (Romeis, Ochs, Borbe) .
- In vitro bonding of Cetrorelix to LHRH receptors on the pituitary gland of swine is mentioned. Also mentioned are other possible clinical areas of application, including hormone- dependent tumors .
- Cetrorelix was administered intermittently according to a specified therapy scheme
- Figure 1 is a summary of the clinical results for specific Cetrorelix dosage regimens PLA refers to a placebo
- Figure 2 (a) shows the effect of the C01 and C I O treatments on prostate size PLA refers to a placebo
- TREATMENTS C01 refers to a dosage regimen of 1 mg/day s c for 28 days and a 3 months follow-up observation period
- CIO refers to a dosage regimen of 10 mg day for the first one to five days followed by a dosage regime of 1 mg/day s c for 28 days and a 3 months follow-up observation period
- Figure 2 (b) illustrates the absolute changes in prostate size from baseline for the CO 1 and CIO
- Figure 3 (a) shows the number of patients with an I-PSS improvement > 40% and also with an improvement > 30% resulting from the treatment COl and C I O (defined above)
- PLA is the placebo 1-PSS (International Prostate Symptom Score) includes the following indicia of 1 ) feeling of incomplete voiding, 2) increased frequency of voiding, 3) dribbling, 4) dilficulties to postpone voiding 5) weak urinary stream 6) increased effort to start voiding and 7) nvctu ⁇ a.
- Figure 3 (b) shows the l-PSS improvement with the C IO and COl treatments (defined above) over 120 days, including the observational follow-up period
- Figure 4 (a) shows the improvement in maximum uroflow > 3 ml/sec C IO and CO l (defined above) treatment phases
- PLA is the placebo
- Figure 4 (b) shows the rate of uroflow as a function of the COl and CI O treatments (defined above) over a 120 day period
- Cetrorelix is administered in a dose of 0.5 mg to 2 mg daily for 4 to 8 weeks for the therapy of BPH.
- a dose of 5 mg to 30 mg, dispensed once per week or every 10 days also over a time period of 4 to 8 weeks as well as one every two weeks or one injection per month of 20 mg to 60 mg can also decisively improve the clinical symptoms and signs.
- Submaximal decreases of testosterone occur, but these are above those levels associated with castration.
- the prostate volume decreases by 20 to 40 % during the treatment time of 4 to 8 weeks .
- This therapy represents a significant therapeutic advance in the treatment of BPH since it not only achieves an improvement of the clinical symptoms of BPH but also a diminution of the prostate and an improvement of the urine flow like those associated with surgery
- the protocols of the invention avoid the negative consequences of an operation, e g urine incontinence, retrograde ejaculation, blood loss with the consequence of blood transfusions and also the risks of infection associated with surgery
- Cetrorelix is administered with ⁇ -reductase inhibitors or ⁇ -receptor blocking agents to a patient as follows
- Cetrorelix is administered to the patient followed by a 1 - 12 week period where an ⁇ -reductase inhibitor of 5 mg/day, an ⁇ -receptor blocking agent in the dose range of 2 mg to 10 mg/day or of 0 1 mg to 0 4 mg/day dependent on each agent or a drug of natural origin 1-6 capsules or tablets/day used for the treatment of BPH is administered
- Cetrorelix can be administered for a 1 to 12 weeks period followed by retreatment with Cetrorelix after one to six months
- 5 ⁇ -reductase inhibitors or ⁇ -blockers such as Naftopidil has decided benefits which occur quickly and are long-lasting
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (21)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
UA99042044A UA62941C2 (en) | 1996-09-12 | 1997-01-09 | A regime for therapeutic management of a benign prostatic hyperplasia and prostatic cancer employs Cetrorelix alone or in combination with inhibitors or blocking agents. The regimen reduces the volume of the prostate and avoids the side effects associated with testosterone levels being in a castration range. Cetrorelix is administered at dosages between 0.5 mg/day and 20 mg/week or about 0.014 mg/kg body weight per day to 0.30 mg/kg body weight per week or at levels of about 25 to 120 mg of Cetrorelix per month or 0.376 mg/kg to 1.71 mg/kg per month. Cetrorelix can be administered with inhibitors or blocking agents. |
DK97944818T DK0925069T3 (en) | 1996-09-12 | 1997-09-01 | Use of Cetrorelix for the treatment of benign prostate hypertrophy and prostate cancer |
EEP199900121A EE04000B1 (en) | 1996-09-12 | 1997-09-01 | A pharmaceutical preparation for the treatment of prostate hypertrophy and prostate carcinoma |
SI9730769T SI0925069T1 (en) | 1996-09-12 | 1997-09-01 | Use of cetrorelix for the treatment of benign prostate hypertrophy and prostate cancer |
MXPA99002420A MXPA99002420A (en) | 1996-09-12 | 1997-09-01 | Means for treating prostate hypertrophy and prostate cancer. |
NZ334540A NZ334540A (en) | 1996-09-12 | 1997-09-01 | Use of cetrorelix as a LH-RH antagonist for treating prostate hypertrophy and prostate cancer |
EP97944818A EP0925069B1 (en) | 1996-09-12 | 1997-09-01 | Use of cetrorelix for the treatment of benign prostate hypertrophy and prostate cancer |
SK301-99A SK286174B6 (en) | 1996-09-12 | 1997-09-01 | Use of cetrorelix for the manufacture of a medicament for the treatment of BPH or prostatic cancer |
IL12833197A IL128331A0 (en) | 1996-09-12 | 1997-09-01 | Pharmaceutical compositions for the treatment of prostate hypertrophy and prostate cancer |
JP10513204A JP2001500500A (en) | 1996-09-12 | 1997-09-01 | Means for treating prostatic hypertrophy and prostate cancer |
PL332085A PL193184B1 (en) | 1996-09-12 | 1997-09-01 | Means for treating prostate hypertrophy and prostate cancer |
CZ80899A CZ298738B6 (en) | 1996-09-12 | 1997-09-01 | Preparation for treating prostate hypertrophy and prostate cancer |
HU0000261A HUP0000261A3 (en) | 1996-09-12 | 1997-09-01 | Means for treating prostate hypertrophy and prostate cancer |
AU46198/97A AU738306B2 (en) | 1996-09-12 | 1997-09-01 | Means for treating prostate hypertrophy and prostate cancer |
BR9713197-0A BR9713197A (en) | 1996-09-12 | 1997-09-01 | Means for treating prostate hypertrophy and prostate cancer |
DE69738045T DE69738045T2 (en) | 1996-09-12 | 1997-09-01 | USE OF CETRORELIX FOR THE TREATMENT OF BENEFICIAL PROSTATE HYPERTROPHY AND PROSTATE CANCER |
IL128331A IL128331A (en) | 1996-09-12 | 1999-02-02 | Pharmaceutical compositions for the treatment of prostate hypertrophy and prostate cancer |
IS4978A IS4978A (en) | 1996-09-12 | 1999-02-16 | Method of Treatment of Prostate Enlargement and Prostate Cancer |
NO19991192A NO326207B1 (en) | 1996-09-12 | 1999-03-11 | Use of the compound Cetrorelix for the preparation of a drug for the treatment of prostate hypertrophy and prostate cancer |
HK00100793A HK1021937A1 (en) | 1996-09-12 | 2000-02-11 | Use of luteinizing hormone releasing hormone in the manufacture of a medicament for treating benign hypertrophy and prostate cancer |
IL189132A IL189132A0 (en) | 1996-09-12 | 2008-01-30 | Pharmaceutical compositions for the treatment of prostate hypertrophy and prostate cancer |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2599096P | 1996-09-12 | 1996-09-12 | |
US60/025,990 | 1996-09-12 | ||
US4322897P | 1997-04-10 | 1997-04-10 | |
US60/043,228 | 1997-04-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998010781A1 true WO1998010781A1 (en) | 1998-03-19 |
Family
ID=26700570
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1997/004740 WO1998010781A1 (en) | 1996-09-12 | 1997-09-01 | Means for treating prostate hypertrophy and prostate cancer |
Country Status (29)
Country | Link |
---|---|
US (4) | US6054432A (en) |
EP (1) | EP0925069B1 (en) |
JP (1) | JP2001500500A (en) |
KR (1) | KR100546235B1 (en) |
CN (1) | CN1126566C (en) |
AR (1) | AR009757A1 (en) |
AT (1) | ATE370743T1 (en) |
AU (1) | AU738306B2 (en) |
BR (1) | BR9713197A (en) |
CA (1) | CA2215015A1 (en) |
CZ (1) | CZ298738B6 (en) |
DE (1) | DE69738045T2 (en) |
DK (1) | DK0925069T3 (en) |
EE (1) | EE04000B1 (en) |
ES (1) | ES2289764T3 (en) |
HK (1) | HK1021937A1 (en) |
HU (1) | HUP0000261A3 (en) |
IL (3) | IL128331A0 (en) |
IS (1) | IS4978A (en) |
MX (1) | MXPA99002420A (en) |
NO (1) | NO326207B1 (en) |
NZ (1) | NZ334540A (en) |
PL (1) | PL193184B1 (en) |
PT (1) | PT925069E (en) |
RU (1) | RU2215537C2 (en) |
SK (1) | SK286174B6 (en) |
TR (1) | TR199900556T2 (en) |
TW (1) | TWI224002B (en) |
WO (1) | WO1998010781A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003011314A2 (en) * | 2001-07-31 | 2003-02-13 | Zentaris Gmbh | Use of lhrh-antagonists for the improvement of t-cell mediated immunity |
JP2004506647A (en) * | 2000-08-17 | 2004-03-04 | ツェンタリス アクチエンゲゼルシャフト | Method for producing peptide salt, its use, pharmaceutical preparation containing said peptide salt |
US6828415B2 (en) * | 1993-02-19 | 2004-12-07 | Zentaris Gmbh | Oligopeptide lyophilisate, their preparation and use |
US6989400B2 (en) | 2003-01-17 | 2006-01-24 | Threshold Pharmaceuticals, Inc. | Treatment of benign prostatic hyperplasia |
EP1967202A1 (en) * | 2007-03-05 | 2008-09-10 | AEterna Zentaris GmbH | Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity |
US20090221569A1 (en) * | 2008-02-29 | 2009-09-03 | Aeterna Zentaris Gmbh | Use of lhrh antagonists for intermittent treatments |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6054432A (en) * | 1996-09-12 | 2000-04-25 | Asta Medica Aktiengesellschaft | Means for treating prostate hypertrophy and prostate cancer |
FR2768055A1 (en) * | 1997-09-11 | 1999-03-12 | Synthelabo | USE OF SULFONANILIDE DERIVATIVES FOR OBTAINING A MEDICAMENT FOR THE TREATMENT OF RETROGRADE EJACULATION OR ASPPERMIA |
TW536402B (en) * | 1998-06-26 | 2003-06-11 | Yamanouchi Pharma Co Ltd | Pharmaceutical composition for the therapy of voiding dysfunction |
DE19911771B4 (en) * | 1999-03-17 | 2006-03-30 | Zentaris Gmbh | LHRH antagonist, process for its preparation and its use |
US7129262B2 (en) * | 1999-07-23 | 2006-10-31 | The Regents Of The University Of California | Indole compounds useful for the treatment of cancer |
US6545034B1 (en) * | 1999-07-23 | 2003-04-08 | The Regents Of The University Of California | Use of etodolac for the treatment of chronic lymphocytic leukemia |
US7361680B2 (en) * | 1999-07-23 | 2008-04-22 | The Regents Of The University Of California | Indole compounds useful for the treatment of cancer |
US7151100B1 (en) * | 1999-07-23 | 2006-12-19 | The Regents Of The University Of California | Indole compounds useful for the treatment of cancer |
US7105560B1 (en) | 1999-07-23 | 2006-09-12 | The Regents Of The University Of California | Use of etodolac in the treatment of multiple myeloma |
CA2370501C (en) * | 1999-08-09 | 2008-09-16 | Yamanouchi Pharmaceutical Co., Ltd. | Pharmaceutical composition for the therapy of lower urinary tract symptoms |
PT1955700E (en) | 1999-09-30 | 2011-05-04 | Harbor Biosciences Inc | Therapeutic treatment of androgen receptor driven conditions |
US20040152672A1 (en) * | 2000-08-09 | 2004-08-05 | Carson Dennis A. | Indole compounds useful for the treatment of cancer |
KR100876538B1 (en) * | 2000-08-17 | 2008-12-31 | 아에테르나 젠타리스 게엠베하 | Method for preparing salts of LHRH antagonists |
JP2001288115A (en) * | 2001-02-07 | 2001-10-16 | Yamanouchi Pharmaceut Co Ltd | Remedy for lower urinary tract symptom |
WO2004026116A2 (en) * | 2002-09-19 | 2004-04-01 | The Regents Of The University Of California | Use of etodoclac to treat hyperplasia |
GB0301016D0 (en) * | 2003-01-16 | 2003-02-19 | Univ London | Treatment of benign prostatic hyperplasia |
ZA200810058B (en) * | 2006-05-03 | 2010-09-29 | Wisconsin Alumni Res Found | N1-N4-bis(buta-1,3-dienyl)butane-1,4-diamine pharmaceutical compositions and methods thereof |
EP1891964A1 (en) * | 2006-08-08 | 2008-02-27 | AEterna Zentaris GmbH | Application of initial doses of LHRH analogues and maintenance doses of LHRH antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits |
US10585101B2 (en) | 2016-03-10 | 2020-03-10 | Wavesense, Inc. | Prostatic liquid biopsy for the detection of prostate cancer and benign prostatic hyperplasia |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2218335A (en) * | 1988-05-10 | 1989-11-15 | Innofinance Altalanos Innovaci | Use of gonadoliberin derivatives for preparing tumour-inhibiting pharmaceutical compositions |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3918543A1 (en) * | 1989-06-07 | 1990-12-13 | Boehringer Mannheim Gmbh | USE OF NAFTOPIDIL FOR THE THERAPY OF DYSURIA IN BENIGNER PROSTATE HYPERTROPHY |
IL101245A0 (en) * | 1991-03-20 | 1992-11-15 | Merck & Co Inc | Pharmaceutical compositions for the treatment of prostatic cancer |
US6054432A (en) * | 1996-09-12 | 2000-04-25 | Asta Medica Aktiengesellschaft | Means for treating prostate hypertrophy and prostate cancer |
-
1997
- 1997-08-07 US US08/908,198 patent/US6054432A/en not_active Expired - Fee Related
- 1997-09-01 MX MXPA99002420A patent/MXPA99002420A/en unknown
- 1997-09-01 KR KR1019997002053A patent/KR100546235B1/en not_active IP Right Cessation
- 1997-09-01 DK DK97944818T patent/DK0925069T3/en active
- 1997-09-01 AT AT97944818T patent/ATE370743T1/en not_active IP Right Cessation
- 1997-09-01 PL PL332085A patent/PL193184B1/en not_active IP Right Cessation
- 1997-09-01 SK SK301-99A patent/SK286174B6/en not_active IP Right Cessation
- 1997-09-01 DE DE69738045T patent/DE69738045T2/en not_active Expired - Lifetime
- 1997-09-01 AU AU46198/97A patent/AU738306B2/en not_active Ceased
- 1997-09-01 EP EP97944818A patent/EP0925069B1/en not_active Expired - Lifetime
- 1997-09-01 WO PCT/EP1997/004740 patent/WO1998010781A1/en active IP Right Grant
- 1997-09-01 EE EEP199900121A patent/EE04000B1/en not_active IP Right Cessation
- 1997-09-01 BR BR9713197-0A patent/BR9713197A/en not_active Application Discontinuation
- 1997-09-01 NZ NZ334540A patent/NZ334540A/en unknown
- 1997-09-01 RU RU99107280/14A patent/RU2215537C2/en not_active IP Right Cessation
- 1997-09-01 ES ES97944818T patent/ES2289764T3/en not_active Expired - Lifetime
- 1997-09-01 PT PT97944818T patent/PT925069E/en unknown
- 1997-09-01 JP JP10513204A patent/JP2001500500A/en active Pending
- 1997-09-01 CZ CZ80899A patent/CZ298738B6/en not_active IP Right Cessation
- 1997-09-01 HU HU0000261A patent/HUP0000261A3/en unknown
- 1997-09-01 IL IL12833197A patent/IL128331A0/en unknown
- 1997-09-01 CN CN97197904A patent/CN1126566C/en not_active Expired - Fee Related
- 1997-09-01 TR TR1999/00556T patent/TR199900556T2/en unknown
- 1997-09-10 TW TW086113121A patent/TWI224002B/en active
- 1997-09-10 CA CA002215015A patent/CA2215015A1/en not_active Abandoned
- 1997-09-11 AR ARP970104168A patent/AR009757A1/en not_active Application Discontinuation
-
1998
- 1998-04-09 US US09/057,458 patent/US5998377A/en not_active Expired - Fee Related
- 1998-04-20 US US09/062,704 patent/US6071882A/en not_active Expired - Fee Related
-
1999
- 1999-02-02 IL IL128331A patent/IL128331A/en not_active IP Right Cessation
- 1999-02-16 IS IS4978A patent/IS4978A/en unknown
- 1999-03-11 NO NO19991192A patent/NO326207B1/en not_active IP Right Cessation
- 1999-09-22 US US09/401,851 patent/US6300313B1/en not_active Expired - Fee Related
-
2000
- 2000-02-11 HK HK00100793A patent/HK1021937A1/en not_active IP Right Cessation
-
2008
- 2008-01-30 IL IL189132A patent/IL189132A0/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2218335A (en) * | 1988-05-10 | 1989-11-15 | Innofinance Altalanos Innovaci | Use of gonadoliberin derivatives for preparing tumour-inhibiting pharmaceutical compositions |
Non-Patent Citations (2)
Title |
---|
GONZALEZ-BARCENA ET AL: "RESPONSES TO THE ANTAGONISTIC ANALOG OF LH-RH (SB-75, CETROLIX) IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA AND PROSTATIC CANCER", THE PROSTATE, vol. 24, 1994, pages 84 - 92, XP002054664 * |
OESTERLING: "ENDOCRINE THERAPIES FOR SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA", SUPPLEMENT TO UROLOGY, vol. 43, no. 2, 1994, pages 7 - 16, XP002054665 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6828415B2 (en) * | 1993-02-19 | 2004-12-07 | Zentaris Gmbh | Oligopeptide lyophilisate, their preparation and use |
JP2004506647A (en) * | 2000-08-17 | 2004-03-04 | ツェンタリス アクチエンゲゼルシャフト | Method for producing peptide salt, its use, pharmaceutical preparation containing said peptide salt |
WO2003011314A2 (en) * | 2001-07-31 | 2003-02-13 | Zentaris Gmbh | Use of lhrh-antagonists for the improvement of t-cell mediated immunity |
WO2003011314A3 (en) * | 2001-07-31 | 2003-10-16 | Zentaris Gmbh | Use of lhrh-antagonists for the improvement of t-cell mediated immunity |
US6989400B2 (en) | 2003-01-17 | 2006-01-24 | Threshold Pharmaceuticals, Inc. | Treatment of benign prostatic hyperplasia |
EP1967202A1 (en) * | 2007-03-05 | 2008-09-10 | AEterna Zentaris GmbH | Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity |
WO2008107446A1 (en) * | 2007-03-05 | 2008-09-12 | Æterna Zentaris Gmbh | Use of lhrh antagonists for the treatment of lower urinary tract symptoms, in particular overactive bladder and/or detrusor overactivity |
US20090221569A1 (en) * | 2008-02-29 | 2009-09-03 | Aeterna Zentaris Gmbh | Use of lhrh antagonists for intermittent treatments |
US8273716B2 (en) * | 2008-02-29 | 2012-09-25 | Spectrum Pharmaceuticals, Inc. | Use of LHRH antagonists for intermittent treatments |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5998377A (en) | Means for treating prostate cancer | |
Weckermann et al. | Hormone therapy in prostate cancer: LHRH antagonists versus LHRH analogues | |
JP3350048B2 (en) | Methods for treating androgen-related diseases | |
EP0480950B1 (en) | Combination therapy for prophylaxis and/or treatment of benign prostatic hyperplasia | |
US6423698B1 (en) | Combination therapy for the prophylaxis and/or treatment of benign prostatic hyperplasia | |
Denis | Prostate cancer. Primary hormonal treatment | |
JP2000513326A (en) | Method for treating prostate cancer using LHRH antagonists | |
MXPA04009455A (en) | Enhancement of endogenous gonadotropin production. | |
Jacobi et al. | Gonadotropin-releasing hormone analogues for prostate cancer: untoward side effects of high-dose regimens acquire a therapeutical dimension | |
EP1029868A1 (en) | Hysteromyoma remedy containing dienogest as the active ingredient | |
Moghissi | Clinical applications of gonadotropin-releasing hormones in reproductive disorders | |
Leewansangtong et al. | Maximal androgen withdrawal for prostate cancer therapy: current status and future potential | |
UA62941C2 (en) | A regime for therapeutic management of a benign prostatic hyperplasia and prostatic cancer employs Cetrorelix alone or in combination with inhibitors or blocking agents. The regimen reduces the volume of the prostate and avoids the side effects associated with testosterone levels being in a castration range. Cetrorelix is administered at dosages between 0.5 mg/day and 20 mg/week or about 0.014 mg/kg body weight per day to 0.30 mg/kg body weight per week or at levels of about 25 to 120 mg of Cetrorelix per month or 0.376 mg/kg to 1.71 mg/kg per month. Cetrorelix can be administered with inhibitors or blocking agents. | |
US6613758B1 (en) | Method for treating osteoporosis in castrated prostatic cancer patients | |
Vacher | Gn-RH agonists in the treatment of prostatic carcinoma | |
Blom et al. | On the Management of Metastatic Prostate Cancer with LH-RH Analogs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 97197904.9 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BR CN CZ EE HU IL IS JP KR LT LV MX NO NZ PL RO RU SG SI SK TR UA |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1997944818 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 30199 Country of ref document: SK |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV1999-808 Country of ref document: CZ Ref document number: 334540 Country of ref document: NZ |
|
ENP | Entry into the national phase |
Ref document number: 1998 513204 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019997002053 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/1999/002420 Country of ref document: MX Ref document number: 1999/00556 Country of ref document: TR |
|
WWP | Wipo information: published in national office |
Ref document number: 1997944818 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: PV1999-808 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: 1019997002053 Country of ref document: KR |
|
WWR | Wipo information: refused in national office |
Ref document number: 1019997002053 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 1997944818 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: PV1999-808 Country of ref document: CZ |